<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137380</url>
  </required_header>
  <id_info>
    <org_study_id>16766</org_study_id>
    <secondary_id>I6T-MC-AMBD</secondary_id>
    <nct_id>NCT04137380</nct_id>
  </id_info>
  <brief_title>A Study of Mirikizumab in Healthy Chinese Participants</brief_title>
  <official_title>A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug known as&#xD;
      mirikizumab. The study will investigate how the body processes the study drug. It will last&#xD;
      up to about 4 months for each participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Actual">December 11, 2020</completion_date>
  <primary_completion_date type="Actual">December 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>PK: Cmax of Mirikizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC from time zero to infinity (AUC[0-∞]) of Mirikizumab</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>PK: AUC(0-∞) of Mirikizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC from Time Zero to Time T, where T is the Last Sample with a Measurable Concentration (AUC[0-tlast]) of Mirikizumab</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>PK: AUC(0-tlast) of Mirikizumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mirikizumab - Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab - Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Mirikizumab - Intravenous (IV)</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab - Subcutaneous (SC)</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Native Chinese (all 4 biological grandparents and both biological parents to be&#xD;
             Chinese origin)&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²),&#xD;
             inclusive, at time of screening&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range for the&#xD;
             investigative site or results with acceptable deviations that are judged to be not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling and administration of&#xD;
             investigational product (IP) or placebo&#xD;
&#xD;
          -  Are reliable and willing to be available for the duration of the study and are willing&#xD;
             to follow study procedures&#xD;
&#xD;
          -  Are able and willing to give signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in a clinical study involving an IP or any other type of&#xD;
             medical research judged not to be scientifically or medically compatible with this&#xD;
             study&#xD;
&#xD;
          -  Have participated in a clinical trial involving an IP within 30 days or 5 half-lives&#xD;
             (whichever is longer) prior to screening. If the clinical trial involved treatment&#xD;
             with biologic agents (such as monoclonal antibodies, including marketed drugs), at&#xD;
             least 3 months or 5 half-lives (whichever is longer) should have elapsed prior to Day&#xD;
             1&#xD;
&#xD;
          -  Have known allergies to LY3074828, humanized monoclonal antibodies, related compounds&#xD;
             or any components of the formulation, or history of significant atopy&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen or positive&#xD;
             hepatitis B core antibody&#xD;
&#xD;
          -  Have had symptomatic herpes zoster within 3 months of screening&#xD;
&#xD;
          -  Show evidence of active or latent tuberculosis (TB), as documented by medical history,&#xD;
             examination, chest X-rays (posterior/anterior and lateral), and TB testing (positive&#xD;
             or indeterminate for QuantiFERON® -TB Gold test or T-Spot. 1 retest permitted&#xD;
             following indeterminate result); or have had household contact with a person with&#xD;
             active TB, unless appropriate and documented prophylaxis treatment has been given.&#xD;
             Participants with any history of active TB are excluded from the study, regardless of&#xD;
             previous or current TB treatments.&#xD;
&#xD;
          -  Have received live vaccine(s), including attenuated live vaccines and those&#xD;
             administered intranasally, within 8 weeks of screening, or intend to during the study&#xD;
&#xD;
          -  Are immunocompromised&#xD;
&#xD;
          -  Have clinically significant multiple or severe drug allergies, or intolerance to&#xD;
             topical corticosteroids, or severe post treatment hypersensitivity reactions&#xD;
             (including, but not limited to, erythema multiforme major, linear immunoglobulin A&#xD;
             dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Xuhui District</city>
        <state>Shanghai</state>
        <zip>20031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 15, 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirikizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

